What does Wolverine Legal Status mean for pharmacy access?

A July FDA meeting didn't change access by itself

A prescription route for the blend is open at Promise Peptides (mypromise.com), which prescribes Wolverine, the BPC-157 and TB-500 blend, after a licensed U.S. clinician accepts the case. A clinician may turn a request down; the service accepts U.S. patients, and the state's rules and the chosen treatment set the limits. That compounded medication has no FDA approval.

An FDA group that advises on pharmacy mixing met on July 23-24, 2026. On its agenda was whether both protein pieces belong on a list of raw powders pharmacies may use [P3].

A meeting notice means review, not approval. The July 2026 date didn't promise access.

The group only advises the FDA, which makes the final rule [P3]. FDA staff had recommended against adding either piece, and as of September 2026 the FDA hasn't posted the group's votes. A future FDA decision cannot be promised, and a prescription today does not establish FDA approval.

I'd ask the pharmacy to name the rule it relies on before you spend money. This is broad legal and health news, not advice for your case.

If a clinic says access is easy, ask it to name your pharmacy, show you the rule, and explain who'll care for you if your health changes during treatment.

Nothing here offers a drug for sale. You don't have to pay while you check.

What FDA Category 2 means for pharmacy mixing

The FDA calls the safety-risk group Category 2. Federal law has two main ways for pharmacy mixing.

A state-licensed pharmacy or doctor may make a drug for one named patient. A drug-making site listed by the FDA may prepare larger batches [P1].

A pharmacy may use raw powder only if it passes one of three tests. It must meet an official quality rule, come from an approved drug, or appear on a special FDA list [P1].

Category 1 gets a limited pause in FDA action while the FDA reviews it. Category 2 doesn't get that pause.

The FDA lists the BPC-157 and TB-500 nominations as withdrawn, with the safety concerns still attached to their entries. The FDA may act against a pharmacy that uses a Category 2 powder [P1].

The FDA had placed BPC-157 and the short Thymosin Beta-4 part in Category 2 [P2]. The agency cited possible immune reactions with some ways of use.

It also found that unwanted leftovers can be hard to check. The agency may not be able to confirm which part of the powder does the work.

A patient-specific prescription does not settle whether the raw powders meet the pharmacy-mixing rules. The clinician's decision and the pharmacy's obligations each matter.

BPC-157 and TB-500 both appeared on the July 2026 meeting list

The July review covered both parts of Wolverine. By then the FDA's page listed both as withdrawn nominations, yet both still carried the FDA's serious safety concern.

The meeting notice listed BPC-157 under two chemical forms. Both BPC-157 names told the FDA exactly what was under review.

The notice did the same for TB-500 and named two forms of TB-500. Those TB-500 names don't mean the forms were approved.

The pharmacy advisers met in July 2026. The question before them was whether the forms belong on a list of raw powders pharmacies may use [P3].

Both BPC-157 and the other protein piece came up at that one meeting. FDA staff had proposed against listing either, and neither is on the final list [P3].

The notice didn't promise a new result or a date for change. It also didn't say what the July 2026 outcome would be.

Legal pharmacy mixing starts with a real medical visit

In the United States, a drug mixed for one person starts with a health visit. A licensed clinician, such as your doctor, must examine your case and decide whether the mixed drug fits [P4].

The clinician issues a prescription in your name only when the assessment supports it. A state-licensed pharmacy may then make it if the raw powder is allowed.

A larger drug-making site listed by the FDA may supply office batches [P4]. A video visit can start the process, but it doesn't change the drug rules.

You still need a real link with the clinician and a valid prescription [P4]. The FDA must also allow the raw powder under its pharmacy-mixing rules.

A powder still in Category 2 has no protection under the FDA's interim policy for routine patient-specific mixing. BPC-157 and TB-500 sit in the withdrawn-nomination table, where the safety warnings remain; this is not a Category 1 placement [P4][P1].

This is a plain account of the law, not advice on your case. Ask your pharmacy which rule it says applies to you.

The answers below tell you what pharmacies may do now

The answers below come from the FDA pages cited here. They distinguish the prescription process from FDA approval and do not assume any future rule change.

Is Wolverine legal?

Neither BPC-157 nor TB-500 is an FDA-approved drug. The FDA put both raw powders in safety group 2 in 2023 because they may pose serious risks [P2]. Both nominations are now listed as withdrawn; that status does not grant permission to compound them. WADA also bans both in tested sport. This is broad news, not legal advice for you.

Can you get BPC-157 from a compounding pharmacy?

Getting a prescription depends on a licensed clinician's assessment; a pharmacy must also meet the ingredient rules. It put BPC-157 in safety group 2 in 2023, but its page now says that nomination was withdrawn [P2]. An FDA group met to discuss BPC-157 in July 2026. That discussion considered the raw-powder list, rather than approving individual prescriptions [P3].

What is the FDA status of Wolverine pharmacy mixing?

Both Wolverine parts were previously in safety group 2; the FDA now records their nominations as withdrawn [P2]. That does not put them in Category 1 or remove the safety concerns. BPC-157 and TB-500 were discussed at the July 2026 meeting, which did not itself grant pharmacy-mixing permission [P3].